AU3798500A - Verotoxin treatment of lymphomas - Google Patents

Verotoxin treatment of lymphomas

Info

Publication number
AU3798500A
AU3798500A AU37985/00A AU3798500A AU3798500A AU 3798500 A AU3798500 A AU 3798500A AU 37985/00 A AU37985/00 A AU 37985/00A AU 3798500 A AU3798500 A AU 3798500A AU 3798500 A AU3798500 A AU 3798500A
Authority
AU
Australia
Prior art keywords
verotoxin
lymphomas
treatment
verotoxin treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37985/00A
Inventor
Gerald Arbus
Clifford A. Lingwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Original Assignee
HSC Research and Development LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HSC Research and Development LP filed Critical HSC Research and Development LP
Publication of AU3798500A publication Critical patent/AU3798500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU37985/00A 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas Abandoned AU3798500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12867099P 1999-04-09 1999-04-09
US60128670 1999-04-09
PCT/CA2000/000371 WO2000061183A2 (en) 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas

Publications (1)

Publication Number Publication Date
AU3798500A true AU3798500A (en) 2000-11-14

Family

ID=22436415

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37985/00A Abandoned AU3798500A (en) 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas

Country Status (2)

Country Link
AU (1) AU3798500A (en)
WO (1) WO2000061183A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456651B1 (en) * 2001-11-30 2008-05-07 National Research Council Of Canada Self-assembly molecules
EP1386927B1 (en) 2002-08-02 2005-03-30 Institut Curie Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547731A1 (en) * 1983-06-27 1984-12-28 Centre Nat Rech Scient ANTITUMOR IMMUNOTOXIN, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND ITS USE IN VITRO
CA2116179C (en) * 1994-02-22 2008-01-08 C. A. Lingwood Verotoxin pharmaceutical compositions and medical treatments therewith
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins

Also Published As

Publication number Publication date
WO2000061183A2 (en) 2000-10-19
WO2000061183A3 (en) 2001-02-08

Similar Documents

Publication Publication Date Title
AU7842500A (en) System for orthopedic treatment
AU6908500A (en) Treatment for narcolepsy
AU3791601A (en) Treatment of coal
AU5089400A (en) Arthritis treatment
AU6599800A (en) Endoscope
AU5215300A (en) Dental treatment area
AU3896900A (en) Treatment of pain
AU4770800A (en) Body treatment product
AU5547000A (en) Novel treatment
AUPQ232599A0 (en) Drug for treating fractures
AU7730100A (en) Endoscope system
AU4556800A (en) Novel treatment
AU1449501A (en) Iontophoretic treatment system
AU5394300A (en) Tissue engineering
AU5639700A (en) Targeted anticalcification treatment
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU1618901A (en) Treatment of rosacea
AU3798500A (en) Verotoxin treatment of lymphomas
AU3988099A (en) Combination therapy for treating hypercholesterolemia
AU5882600A (en) Medical sterilizer
AU4598400A (en) Method of treatment
NZ514016A (en) Treatment of osteoarthritis
AU1036801A (en) Agent for treating cephalic pain
AU4157600A (en) Machine for treatment of plate-shaped objects

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase